daily oral glp-1 receptor agonist orforglipron for adults with obesity Shows Positive Efficacy, Tolerability in Weight Management Oral GLP-1 confers up to

23 Oct 2024

Subsequently, patients are examined every year after the first year

These agents act on multiple physiological pathways involved in type 2 diabetes with the effect of increasing insulin secretion and decreasing glucagon to control glucose levels (1,2)

The beneficial effects of GLP-1 receptor activation on glycemia occur through several mechanisms: GLP-1 stimulates glucose-dependent insulin secretion from pancreatic -cells, suppresses inappropriately elevated glucagon secretion from pancreatic -cells, delays gastric emptying, and induces satiety via a direct action in the central nervous system

All participants were T2DM patients being treated with a combination of metformin, sodium-glucose co-transporter-2, or sulfonylurea